naa a22 4500 510764452 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s12094-012-0897-9 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0897-9 Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics [Elektronische Daten] [Liyan Wan, Xiao Li, Hong Shen, Xiaoyan Bai] Introduction: Elevated Enhancer of Zeste Homologue 2 (EZH2) expression is involved in many human malignancies through epigenetically silencing related genes. However, the study of the EZH2 protein expression in lung cancer remains at the qualitative or semi-quantitative level. The present study is to elucidate the roles of EZH2 in the progression and metastasis of different subtypes of lung cancer at quantitative level. Materials and methods: Lung carcinoma tissue microarray was constructed containing 32 normal adult lung tissues, 113 lung carcinomas and 57 lymph-node metastases. EZH2 protein expression was detected by immunohistochemistry and assessed quantitatively with Leica Q500MC image analysis system. Positive unit (PU) value was used to evaluate the protein expression intensity of positive cells from systematically selected fields under the microscope. Results: Elevated Enhancer of Zeste Homologue 2 PU in lung carcinomas was significantly greater than that in normal lung tissues (p=0.001). Increased EZH2 expression was correlated with histological subtypes, differentiation, TNM stage, and lymph-node metastases (p<0.05). EZH2 PU of primary lung carcinomas was smaller than that of lymph-node metastasis (p=0.002). EZH2 PU was not associated with patients' gender, age, smoking status, tumor location, and tumor size (p>0.05). Conclusions: Elevated Enhancer of Zeste Homologue 2 PU is increased with the development of lung cancer. EZH2 may play an important role in the progression and metastasis of lung cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Image analysis nationallicence Immunohistochemistry nationallicence EZH2 nationallicence Lung cancer nationallicence Wan Liyan Department of Pathology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, 510515, Guangzhou, Guangdong, People's Republic of China aut Li Xiao Department of Emergency, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China aut Shen Hong Department of Pathology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, 510515, Guangzhou, Guangdong, People's Republic of China aut Bai Xiaoyan Division of Nephrology, Nanfang Hospital, Southern Medical University and Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 132-138 1699-048X 15:2<132 2013 15 12094 https://doi.org/10.1007/s12094-012-0897-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0897-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wan Liyan Department of Pathology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, 510515, Guangzhou, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Li Xiao Department of Emergency, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Shen Hong Department of Pathology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou North Road, 510515, Guangzhou, Guangdong, People's Republic of China aut NATIONALLICENCE 700 1- Bai Xiaoyan Division of Nephrology, Nanfang Hospital, Southern Medical University and Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 132-138 1699-048X 15:2<132 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer